RLAY News and Press, Relay Therapeutics Inc. From 08/08/23

2023-08-08 16:32:54 ET Relay Therapeutics press release ( NASDAQ: RLAY ): Q2 GAAP EPS of -$0.81 beats by $0.01 . Revenue of $0.12M (-67.6% Y/Y) misses by $0.59M . For further details see: Relay Therapeutics GAAP EPS of -$0.81 beats by $0.01, revenue of $0...

Initiated dose expansion cohort for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Updated RLY-2608 600mg BID + fulvestrant data: interim clinical benefit rate of 86% (6 of 7 evaluable patients) & 1 of 5 patients with measu...

CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2023 financial res...

2023-07-28 06:04:46 ET Summary Relay Therapeutics' early clinical data for cancer drug RLY-2608 sparked investor concerns due to lack of robust evidence of efficacy, leading to a 40% stock decline. Despite investor skepticism, analysts believe the sell-off was an overreaction, hig...

2023-05-31 05:55:18 ET Summary Gain Therapeutics is a biotechnology company focused on drug development powered by its SEE-Tx™ target identification platform, which identifies and optimizes binding sites on biological targets that have never before been targeted. The compan...

2023-05-26 08:30:43 ET Palm Beach, FL – May 26, 2023 – FinancialNewsMedia.com News Commentary – Metastatic breast cancer is the advanced stage of breast cancer, including cases wherein cancer has spread to the other parts of the body from the breast. It is a...

CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced complete first-in-human dose e...

2023-05-09 11:58:50 ET Summary Relay is a drug developer using sophisticated modeling techniques to find better binding sites for its drug targets. The company's stock price had been holding up reasonably well despite the savage bear market of 2022 - thanks to some strong bile duc...

2023-05-04 18:07:32 ET Relay Therapeutics press release ( NASDAQ: RLAY ): Q1 GAAP EPS of -$0.78 misses by $0.09 . Revenue of $0.22M (-47.6% Y/Y) beats by $0.06M . Shares -1.96% AH. For further details see: Relay Therapeutics GAAP EPS of -$0.78 mis...

Presented initial clinical data for RLY-2608 at American Association for Cancer Research (AACR) Annual Meeting 2023 Initiated clinical trial for RLY-5836, a chemically-distinct PI3Kα pan-mutant inhibitor $937.8 million in cash, cash equivalents and investments at end of Q...